Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Metastasis | Correction

Correction to: LncRNA MEG3 inhibits melanoma growth, metastasis and formation through modulating miR-21/E-cadherin axis

Authors: Liangcai Wu, Lifei Zhu, Yanchang Li, Zhixin Zheng, Xi Lin, Chaoying Yang

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Excerpt

Following publication of the original article [1], we were notified of a mistake in the article’s title. The title should read “inhibits” instead of “promotes”, as follows: “LncRNA MEG3 inhibits melanoma growth, metastasis and formation through modulating miR-21/E-cadherin axis”. …
Literature
1.
Metadata
Title
Correction to: LncRNA MEG3 inhibits melanoma growth, metastasis and formation through modulating miR-21/E-cadherin axis
Authors
Liangcai Wu
Lifei Zhu
Yanchang Li
Zhixin Zheng
Xi Lin
Chaoying Yang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01239-2

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Abnormal expression and prognostic significance of EPB41L1 in kidney renal clear cell carcinoma based on data mining

Primary research

Long noncoding RNA MIR99AHG promotes gastric cancer progression by inducing EMT and inhibiting apoptosis via miR577/FOXP1 axis

Primary research

Identification of key biomarkers associated with cell adhesion in multiple myeloma by integrated bioinformatics analysis

Primary research

Silencing of microRNA-135b inhibits invasion, migration, and stemness of CD24+CD44+ pancreatic cancer stem cells through JADE-1-dependent AKT/mTOR pathway

Primary research

Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells

Primary research

LNK promotes the growth and metastasis of triple negative breast cancer via activating JAK/STAT3 and ERK1/2 pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits